Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth
Funk, A. L.; Katerji, M.; Afifi, M.; Nyswaner, K.; Woodroofe, C. C.; Edwards, Z. C.; Lindberg, E.; Bergman, K. L.; Gough, N. R.; Rubin, M. R.; Karpinska, K.; Trotter, E. W.; Dash, S.; Ries, A. L.; James, A.; Robinson, C. M.; Difilippantonio, S.; Karim, B. O.; Chang, T. C.; Chen, L.; Xu, X.; Doroshow, J.; Ahel, I.; Marusiak, A.; Swenson, R. E.; Cappell, S. D.; Brognard, J.
Show abstract
The worldwide frequency of head and neck squamous cell carcinoma (HNSCC) is approximately 800,000 new cases, with 430,000 deaths annually. We determined that LZK (encoded by MAP3K13) is a therapeutic target in HNSCC and showed that inhibition with small molecule inhibitors decreases the viability of HNSCC cells with amplified MAP3K13. A drug-resistant mutant of LZK blocks decreases in cell viability due to LZK inhibition, indicating on-target activity by two separate small molecules. Inhibition of LZK catalytic activity suppressed tumor growth in HNSCC PDX models with amplified MAP3K13. We found that the kinase activity of LZK stabilized c-MYC and that LZK stabilized gain-of-function (GOF) p53 through a kinase-independent mechanism. Therefore, we designed proteolysis-targeting chimeras (PROTACs) and demonstrate that our lead PROTAC promotes LZK degradation and suppresses expression of GOF p53 and c-MYC leading to impaired viability of HNSCC cell lines. This research provides a strong basis for development of therapeutics targeting LZK in HNSCCs with amplification of the gene. One Sentence SummaryThis study establishes the kinase LZK as a therapeutic target for HNSCC through regulation of c-MYC expression.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 96%
- Phosphoprotein-based Biomarkers as Predictors for Cancer Therapy 96%
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 95%
Similar papers in this journal
- Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib 96%
- Geometric principles of dendritic integration of excitation and inhibition in cortical neurons 95%
- Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels 95%
Similar papers in this journal
- Discovery of a new class of reversible TEA-domain transcription factor inhibitors with a novel binding mode 96%
- SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species 95%
- Stereo-specific Lasofoxifene Derivatives Reveal the Interplay between Estrogen Receptor Alpha Stability and Antagonistic Activity in ESR1 Mutant Breast Cancer Cells 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.